Saint-Gobain India, a part of the French multinational firm, is a leader in providing glass and glass solutions. But, it is also active in other high-performing sectors that include Performance Plastics (PPL) in Life Sciences. From being leading producers of Performance Plastics to association with pharmaceutical companies for providing medical equipment, to even foraying into the Electric Vehicles segment in India by introducing EV Battery Packs, the PPL- Life Sciences have been aiming for strong growth. During an interaction with BioSpectrum, Ritesh Patterson, General Manager, Performance Plastics, Saint-Gobain India, Bengaluru shares his insights about the company's strategies in the biopharma and medical industries. Edited excerpts;
EC Mergers & Acquisitions advised Equflow on its Sale to Saint-Gobain Life Sciences
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
EC Mergers & Acquisitions advised Equflow on its Sale to Saint-Gobain Life Sciences
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Saint-Gobain Life Sciences Acquires Equflow B V
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Saint-Gobain Life Sciences Introduces Highly Efficient Cell Culture Bags for T Cell Expansion
Saint-Gobain Life Sciences, an industry leader in material science-based solutions for cell and gene therapy manufacturing, today launched a new cell culture bag designed specifically for T cell derived therapies.
T cell based therapies are revolutionizing the approach to treating cancer. Harnessing the patient’s own immune system by isolating their T cells and engineering them to elicit an immune response is emerging as a preferred manufacturing practice. As the industry continues the advancement of these therapies, process efficiency becomes paramount to the success of delivering affordable therapies to patients.